Structural And Biochemical Studies Confirming The Mechanism Of Action Of Asciminib, An Agent Specifically Targeting The Abl Myristoyl Pocket (Stamp)
BLOOD(2020)
摘要
Tyrosine kinase inhibitors (TKIs) that inhibit the transphosphorylation activity of the BCR-ABL1 oncoprotein by binding the ATP-binding site of the catalytic domain of protein kinases are well established as being effective drugs for the treatments of chronic myeloid leukemia (CML). However, the off-target kinase activities of these non-specific TKIs are associated with adverse events that can limit their suitability for the treatment of patients and can negatively impact quality of life. Therefore, a new drug combining high efficacy with minimal side-effects could provide substantial therapeutic advantages.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络